In colorectal, and head and neck cancers, KRAS mutation, EGFR-S492R mutation, and increased ErBb signaling are responsible for resistance against Cetuximab (Dienstmann et al., 2012; Holohan et al., 2013). This evidence concerns the gene EGFR and head and neck cancer.